Treatment options in patients with systemic sclerosis-associated interstitial lung disease

Toby Maher discusses the results of the SENSCIS trial, looking at
the safety and efficacy of nintedanib in systemic
sclerosis-associated interstitial lung disease (SSc-ILD) treated
with mycophenolate.

Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext


Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv